Source: http://www.google.es/patents/US9198863
Timestamp: 2018-01-16 10:09:08
Document Index: 302068628

Matched Legal Cases: ['Application No. 60', '§ 1', 'application No. 200910132824', 'application No. 200810125922', 'Application No. 155', 'application No. 01992565', 'application No. 10', '§ 1', 'Application No. 2001', 'Application No. 2014', 'Application No. 2006', 'Application No. 10177508', 'Application No. 10180945', 'art 1', 'application No. 2013', 'Application No. 01', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 05019453', 'Application No. 01992565', 'Application No. 10177508', 'Application No. 10179086', 'Application No. 10179087', 'Application No. 10180984', 'Application No. 10181032']

Patente US9198863 - Controlled release hydrocodone formulations - Google Patentes
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material....http://www.google.es/patents/US9198863?utm_source=gb-gplus-sharePatente US9198863 - Controlled release hydrocodone formulations
Número de publicación US9198863 B2
Número de solicitud US 14/727,985
También publicado como CA2427815A1, CA2427815C, CN1479614A, CN100518827C, CN101317825A, CN101653411A, CN103690540A, EP1337244A1, EP1337244A4, EP2263658A1, EP2283829A1, EP2295042A1, EP2932964A1, US6733783, US7514100, US8142811, US8231898, US8361499, US8551520, US8647667, US8715721, US8951555, US9023401, US9056052, US9060940, US9205055, US9205056, US9289391, US9504681, US9517236, US9526724, US9572804, US9572805, US9669023, US9682077, US20020192277, US20040047907, US20090202629, US20110038927, US20120263788, US20130158061, US20130295177, US20130302418, US20140199394, US20150037409, US20150110870, US20150148367, US20150238418, US20150258089, US20150258090, US20150265537, US20160151288, US20160151292, US20160151361, US20160158223, US20160158224, US20170087151, US20170087152, US20170151229, WO2002036099A1
Número de publicación 14727985, 727985, US 9198863 B2, US 9198863B2, US-B2-9198863, US9198863 B2, US9198863B2
Citas de patentes (482), Otras citas (334), Citada por (14), Clasificaciones (29)
US 9198863 B2
1. A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a bitartrate salt of hydrocodone and a poly(alkylene oxide), the dosage form, after administration to a human subject, providing a C24/Cmax hydrocodone ratio of from about 0.55 to about 1.0, wherein
the dosage form is a tablet,
the bitartrate salt of hydrocodone is the only active agent in the dosage form.
2. The dosage form of claim 1, which provides a therapeutic effect for about 24 hours.
3. The dosage form of claim 1, wherein said administration is first administration.
4. The dosage form of claim 1, which comprises a 1,000,000 to 10/000,000 weight-average molecular weight poly(alkylene oxide).
5. The dosage form of claim 4, wherein the poly(alkylene oxide) is poly(ethylene oxide).
6. The dosage form of claim 5, wherein the poly(ethylene oxide) has a 7,000,000 average molecular weight.
7. The dosage form of claim 1, which comprises a poly(ethylene oxide) which has an average molecular weight of at least 400,000.
8. The dosage form of claim 1 which provides a C24/Cmax hydrocodone ratio of 0.55 to 0.85.
9. The dosage form of claim 8, which provides a C24/Cmax hydrocodone ratio of 0.6 to about 0.7.
10. The dosage form of claim 1, which provides a Tmax of hydrocodone at about 8 to about 14 hours after administration of the dosage form.
11. The dosage form of claim 1, which comprises an amount of the hydrocodone bitartrate salt which is equivalent to from about 5 mg to about 60 mg of hydrocodone.
12. A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a bitartrate salt of hydrocodone and a poly(alkylene oxide), the dosage form, after administration to human subjects, providing a mean C24/Cmax hydrocodone ratio of from about 0.55 to about 1.0, wherein
13. The dosage form of claim 12, which provides a therapeutic effect for about 24 hours.
14. The dosage form of claim 12, wherein said administration is first administration.
15. The dosage form of claim 12, which comprises a 1,000,000 to 10/000,000 weight-average molecular weight poly(alkylene oxide).
16. The dosage form of claim 12, wherein the poly(alkylene oxide) is poly(ethylene oxide).
17. The dosage form of claim 16, wherein the poly(ethylene oxide) has a 7,000,000 average molecular weight.
18. The dosage form of claim 12, which provides a mean C24/Cmax hydrocodone ratio of 0.55 to 0.85.
19. The dosage form of claim 18, which provides a mean C24/Cmax hydrocodone ratio of 0.6 to about 0.7.
20. The dosage form of claim 12, which provides a mean Tmax of hydrocodone at about 8 to about 14 hours after administration of the dosage form.
21. A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising hydrocodone or a pharmaceutically acceptable salt thereof and a poly(alkylene oxide), wherein
the dosage form, after administration to a human subject, provides a W50 of hydrocodone of between 4 and 22 hours and a therapeutic effect for about 24 hours,
22. The dosage form of claim 21, wherein said administration is first administration.
23. The dosage form of claim 21, wherein the dosage form provides a C24/Cmax hydrocodone ratio of from about 0.55 to about 1 after said administration.
24. The dosage form of claim 23, which provides C24/Cmax hydrocodone ratio of from 0.55 to about 0.85.
25. The dosage form of claim 24, which provides a C24/Cmax hydrocodone ratio of 0.55 to 0.75.
26. The dosage form of claim 25, which provides a C24/Cmax hydrocodone ratio of 0.6 to about 0.7.
27. The dosage form of claim 21, which provides a Tmax of hydrocodone at about 8 to about 14 hours after administration of the dosage form.
28. A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising hydrocodone or a pharmaceutically acceptable salt thereof and a poly(alkylene oxide), wherein
the dosage form, after administration to human subjects, provides a mean W50 of hydrocodone of between 4 and 22 hours and a therapeutic effect for about 24 hours, wherein
29. The dosage form of claim 28, wherein said administration is first administration.
30. The dosage form of claim 23, which provides a mean C24/Cmax hydrocodone ratio of from 0.55 to about 0.85, and a mean a Tmax of hydrocodone at about 8 to about 14 hours after administration of the dosage form.
This application is a continuation of U.S. patent application Ser. No. 14/612,483, filed on Feb. 3, 2015, now U.S. Pat. No. 9,056,052, which is a continuation of U.S. patent application Ser. No. 14/581,175, filed on Dec. 23, 2014, now U.S. Pat. No. 9,023,401, which is a continuation of U.S. patent application Ser. No. 14/520,032, filed on Oct. 21, 2014, now U.S. Pat. No. 8,951,555, which is a continuation of U.S. patent application Ser. No. 14/210,565, filed on Mar. 14, 2014, now U.S. Pat. No. 9,060,940, which is a continuation of U.S. patent application Ser. No. 13/901,069, filed on May 23, 2013, now U.S. Pat. No. 8,715,721, which is a continuation of U.S. patent application Ser. No. 13/721,293, filed on Dec. 20, 2012, now U.S. Pat. No. 8,551,520, which is a continuation of U.S. patent application Ser. No. 13/535,996, filed on Jun. 28, 2012, now U.S. Pat. No. 8,361,499, which is a continuation of U.S. patent application Ser. No. 12/914,054, filed on Oct. 28, 2010, now U.S. Pat. No. 8,231,898, which is a divisional of U.S. patent application Ser. No. 12/378,586, filed on Feb. 17, 2009, now U.S. Pat. No. 8,142,811, which is a continuation of U.S. patent application Ser. No. 10/660,349, filed on Sep. 11, 2003, now U.S. Pat. No. 7,514,100, which is a continuation of U.S. patent application Ser. No. 10/016,651, filed Oct. 30, 2001, now U.S. Pat. No. 6,733,783, which claims the benefit of U.S. Provisional Application No. 60/244,424, filed Oct. 30, 2000, all hereby incorporated by reference.
Other additional drugs include nontoxic NMDA receptor antagonists such dextrorphan, dextromethorphan, 3-(1-naphthalenyl)-5-(phosphonomethyl)-L-phenylalanine, 3-(1-naphthalenyl)-5-(phosphonomethyl)-DL-phenylalanine, 1-(3,5-dimethylphenyl)naphthalene, and 2-(3,5-dimethylphenyl) naphthalene, 2SR,4RS-4-(((1H-Tetrazol-5-yl)methyl)oxy)piperidine-2-carboxylic acid; 2SR,4RS-4-((((1H-Tetrazol-5-yl)methyl)oxy)methyl)piperidine-2-carboxylic acid; E and Z 2SR-4-(O-(1H-Tetrazol-5-yl)methyl)ketoximino)piperidine-2-carboxylic acid; 2SR,4RS-4-((1H-Tetrazol-5-yl)thio)piperidine-2-carboxylic acid; 2SR,4RS-4-((1H-Tetrazol-5-yl)thio)piperidine-2-carboxylic acid; 2SR,4RS-4-(5-mercapto-1H-Tetrazol-1-yl)piperidine-2-carboxylic acid; 2SR,4RS-4-(5-mercapto-2H-Tetrazol-2-yl)piperidine-2-carboxylic acid; 2SR,4RS-4-(5-mercapto-1H-Tetrazol-1-yl) piperidine-2-carboxylic acid; 2SR,4RS-4-(5-mercapto-2H-Tetrazol-2-yl) piperidine-2-carboxylic acid; 2SR,4RS-4-(((1H-Tetrazol-5-yl)thio)methyl)piperidine-2-carboxylic acid; 2SR,4RS-4-((5-mercapto-1H-Tetrazol-1-yl)methyl) piperidine-2-carboxylic acid; or 2SR,4RS-4-((5-mercapto-2H-Tetrazol-2-yl)methyl)piperidine-2-carboxylic acid, their mixtures and pharmaceutically acceptable salts thereof.
US9023401 * 23 Dic 2014 5 May 2015 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9056052 * 3 Feb 2015 16 Jun 2015 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20140199394 * 14 Mar 2014 17 Jul 2014 Purdue Pharma L.P. Controlled release hydrocodone
7 Adv. Drug Deliv. Rev. Mar, 1, 1999; 36(1):125-141.
12 Advisory Committee Briefing Document, NDA 20/2880, Zohydro™ ER Hydrocodone Bitartrate Extended-Release Capsules, Anesthetic and Analgesic Drug Products Advisory Committee, Dec. 7, 2012.
13 Allowed Claims of U.S. Appl. No. 14/672,894, Sep. 24, 2015.
14 Allowed Claims of U.S. Appl. No. 14/673,447; Sep. 24, 2015.
15 Amendment after final action under 37 C.F.R. § 1.116 filed in connection with U.S. Appl. No. 11/372,857 on Mar. 2, 2015.
16 An English translation of the Decision on Reexamination issued in connection with Chinese patent application No. 200910132824.3 on Nov. 5, 2014.
17 An English translation of the Notice on Reexamination issued in connection with Chinese patent application No. 200810125922.X on Dec. 3, 2014.
18 An English translation of the Office Action issued in connection with Israeli Patent Application No. 155,637 on Nov. 16, 2014.
19 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 12/982,386 on Apr. 18, 2013.
20 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 13/833,263 on May 12, 2014.
21 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 13/833,263 on Nov. 3, 2014.
22 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/094,968 on May 9, 2014.
23 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/094,968 on Nov. 5, 2014.
24 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/483,395 on Oct. 3, 2014.
25 Approval Package for NDA 20-616/5-001 (Kadian®), 1997.
26 Benziger, et al., "A Pharmacokinetic/Pharmacodynamic Study of Controlled-Release Oxycodone", 1997.
27 Brendenberg "New Concepts in Administration of Drugs in Tablet Form: Formulation and Evaluation of a Sublingual Tablet for Rapid Absorption and Presentation of an Individualized Dose Administration System Acta Universitiatis Upsaliensis." Comprehensive Summaries of Uppsa/a Dissertations from the Faculty of Pharmacy 287 83 pp. Uppsala ISBN 91-554-5600-6 (2003).
28 Broomhead, et al., "Kadian™/Kapanol™-A Once Daily Mophine Formulation," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S182 Abs 873, European Conference on Clinical Onclology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
29 Castensen et al., "USP Dissolution IV:Comparison of Methods," J. Pham. Sci 1978, 67(9), pp. 1303-1307.
30 Certain Patients Diary Cards, Drug Disposition Records, Case Reports Forms and listing which apparently correlates patient randomization number with the treatment of dosing regimen assigned to each patient, 2003.
31 Cherry DA, et al., "A comparison of Kapanol™ (A new sustained release morphine formulation), MST Continus™ and morphine solution in cancer patients: Morphine metabolite profiles and renal function," (Abstract 999) International Association for the Study of Pain, 7th World Congress on Pain, Paris Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
32 Cherry DA, et al., "Once a Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles," European Journal of Cancer; Part A General Topics 1995; 31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
33 Claims pending in U.S. Appl. No. 12/982,386 on Jan. 5, 2015.
34 Claims pending in U.S. Appl. No. 12/982,386 on May 7, 2014.
35 Claims pending in U.S. Appl. No. 12/982,386 on Nov. 17, 2014.
36 Claims Pending in U.S. Appl. No. 12/982,386 on Oct. 20, 2014.
37 Claims pending in U.S. Appl. No. 13/833,263 on Jan. 5, 2015.
38 Claims pending in U.S. Appl. No. 13/833,263 on May 7, 2014.
39 Claims pending in U.S. Appl. No. 13/833,263 on Nov. 17, 2014.
40 Claims Pending in U.S. Appl. No. 13/833,263 on Oct. 20, 2014.
41 Claims pending in U.S. Appl. No. 14/094,968 on Jan. 5, 2015.
42 Claims pending in U.S. Appl. No. 14/094,968 on May 7, 2014.
43 Claims pending in U.S. Appl. No. 14/094,968 on Nov. 17, 2014.
44 Claims Pending in U.S. Appl. No. 14/094,968 on Oct. 20, 2014.
45 Claims pending in U.S. Appl. No. 14/483,395 on Jan. 13, 2015.
46 Claims pending in U.S. Appl. No. 14/483,395 on Nov. 17, 2014.
47 Claims Pending in U.S. Appl. No. 14/483,395 on Oct. 20, 2014.
48 Claims pending in U.S. Appl. No. 14/635,198 on Mar. 10, 2015.
49 Claims pending in U.S. Appl. No. 14/635,198 on Mar. 30, 2015.
50 Claims pending in U.S. Appl. No. 14/672,894 on Aug. 21, 2015.
51 Claims pending in U.S. Appl. No. 14/672,894 on Mar. 30, 2015.
52 Claims pending in U.S. Appl. No. 14/673,447 on Aug. 21, 2015.
53 Claims pending in U.S. Appl. No. 14/673,447 on Mar. 30, 2015.
54 Claims pending in U.S. Appl. No. 14/706,699 on Aug. 21, 2015.
55 Claims pending in U.S. Appl. No. 14/727,997 on Aug. 21, 2015.
56 Claims pending in U.S. Appl. No. 14/728,023 on Aug. 21, 2015.
57 Clin. Neuropharmacol (Jan.-Feb. 1999); 22 (1):33-9).
58 Clin. Pharmacokinet (Sep. 1998); 35(3):173-90.
59 Conte. et al., Drug Del.. Ind. Pharm. (1989) 15:2583-2596.
60 D.L. Munday, et al., "Changes in Drug Release Rate 2. Effect of Temperature and Relative Humidity on Polymeric Film Coatings," 5th Cong. Int. Tech. Pharm., 1989, vol. 2, pp. 55-60.
61 Database Medline [Online] US National Library of Medicine (NLM), Bethesda, Md, US; Aug. 1994, Yasuhara H: "Ethnic factors in evaluation of drug efficacy and safety," XP002350633 Database accession No. NLM7927070.
62 Decision to refuse a European Patent application issued in connection with European patent application No. 01992565.0-1464 on Jun. 27, 2014.
63 Decision to refuse a European Patent application issued in connection with European patent application No. 10 180 984.6-1464 on Jul. 9, 2014.
64 Declaration of Benjamin Oshlack filed in U.S. Appl. No. 13/833,263 on Dec. 24, 2014.
65 Declaration of Interference issued in connection with U.S. Appl. Nos. 11/372,857; 13/833,263 and 14/094,968 on Apr. 8, 2015.
66 Declaration under 37 C.F.R. § 1.132 by Gurvinder Singh Rekhi filed in connection with U.S. Appl. No. 11/372,857 on Mar. 6, 2015.
67 Document CA/PL 17/07; "Misuse of Divisional Applications," by the EPO President, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Oct. 5, 2007.
68 Document CA/PL 3/08, presented by epi and other Professional Representatives, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Feb. 14, 2008.
69 Drugs (Jan. 1999); 57(1 ):93-9.
70 E.Beubler, "Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken," Therapiewoche Osterreich, 7,2 (1992), pp. 1-15, English translation.
71 Emami, J. et al, "In vitro-In vivo Correlation: From Theory to Applications", J. Pharm Pharmaceut Sci, (www.cspsCanada.org) 9 (2), 169-189, 2006.
72 Encarta World English Dictionary [North American Edition] 2006 Microsoft Incorporation "Matrix", p. 1, definition 2, http://encarta.msn.com/encnet/features/dictionary/DictionaryResults.aspx?-refid=1861678516 retrieved on Apr. 30, 2006.
73 Encyclopedia of Controlled Drug Delivery, vol. 1, "In vitro-in vivo correlation," pp. 425-435 (1999).
74 Encyclopedia of Controlled Drug Delivery, vol. 2, "Oral drug delivery, small intestine & colon," pp. 698-728 (1999).
75 English Abstract of JP-08157392-A, Jun. 18, 1996.
76 English translation of Office Action issued by Japanese Patent Office in connection with corresponding Japanese Patent Application No. 2001-534353 on May 25, 2010.
77 English translation of the Office Action issued in connection with Japanese Application No. 2014-182108 on Aug. 11, 2015.
78 English Translation of the Office Action issued on Mar. 22, 2011 in connection with Japanese Patent Application No. 2006-3165067.
79 EPI Journal Feb. 2007, pp. 59-60; David Harrison; "Divisional Application a continuing problem" (2007).
80 Eur. J. Pharm. Sci. (Jul. 1999); 8(3):157-9.
81 European Search Report issued in connection with European Application No. 10177508.8-2123 on Sep. 11, 2010.
82 European Search Report issued on Nov. 9, 2010 in connection with European Application No. 10180945.72123.
83 FDA Response to a Citizen Petition, Docket No. FDA-2013-P-0703, Oct. 25, 2013.
84 Flanders, P., et al., "The Control of Drug Release From Conventional Melt Granulation Matrices," Drug Development and Industrial Pharmacy, vol. 13, No. 6, pp. 1001-1022 (1987).
85 Frohof-Hulsmann et al., "Aqueous Ethyl Cellulose Dispersion Containing Plasticizers of Different Water Solubility and Hydroxypropyl Methyl-Cellulose as Coating Material for Diffusion Pellets II: Properties of Sprayed Films", European Journ. of Pharma and Biopharma., vol. 48, pp. 67-75, 1999.
86 Geoffrey K. Gourlay, et al.,"The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions," Journal of Pain and Symtoms Management, vol. 6., No. 7, Oct. 1991, pp. 431-436.
87 Giunchedi et al., J. Pharm. (1991) 77:177-181.
88 Goodman and Gilman's, The Pharmacological Basis of Therapeutics, pp. 7-8 (1990).
89 Gourlay et al., "Proceedings of the 7th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients," Pharmacolinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management vol. 2 pp. 631-643, 1993.
90 Gourlay GK, et al., "A comparison of Kapanol™ (A new sustained release morphine formulation), MST Contius® and morphine solution in cancer patients: pharmacokinetics aspects," (Abstract 998) International Association for the Study of Pain, 7th World Congress on Pain Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
91 Gourlay, et al., "Influence of a High-Fat Metal on the Absorption of Morphine From Oral Solutions," Clin. Pharmacol. Ther., vol. 46, Oct. 1989, pp. 463-468.
92 Gourlay, et al., "Once a Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, In the Treatment of Cancer Pain: Pharmacokinetic Aspects," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S187 Abs 897, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
93 Guidance for Industry, "Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In vivo Correlation" (FDA, 1997).
94 Guidance for Industry, Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/ In Vivo Correlations; US Dept. of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER), Sep. 1997, pp. 1-24.
95 Gustafsson et al., "Characterisation of Particle Properties and Compaction Behaviour of Hydroxypropyl Methylcellulose with Different Degrees of Methoxy/Hydroxypropyl Substitution", EP Journ of Pharmaceutical Sci. 9, pp. 171-184, 1999.
96 H.F. Stowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anesthesia, 1985, vol. 40, pp. 438-440.
97 Hansch C et al.,"Comprehensive Medicinal Chemistry, vol. 5 Biopharmaceutics," Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds, Oxford, Pergamon Press, GB, vol. 5, 1990, pp. 251-278, XP008054499.
98 Hyppola et al.,"Evaluation of Physical Properties of Plasticized Ethyl Cellulose Films Cast From Ethanol Solution Part 1", International Journ. of Pharma., vol. 133, pp. 161-170, 1996.
99 Interference 106,022, Exhibit 1001, Jul. 10, 2015.
100 Interference 106,022, Exhibit 1002, Jul. 10, 2015.
101 Interference 106,022, Exhibit 1003, Jul. 10, 2015.
102 Interference 106,022, Exhibit 1004, Jul. 10, 2015.
103 Interference 106,022, Exhibit 1005, Jul. 10, 2015.
104 Interference 106,022, Exhibit 1006, Jul. 10, 2015.
105 Interference 106,022, Exhibit 1007, Jul. 10, 2015.
106 Interference 106,022, Exhibit 1008, Jul. 10, 2015.
107 Interference 106,022, Exhibit 1009, Jul. 10, 2015.
108 Interference 106,022, Exhibit 1010, Jul. 10, 2015.
109 Interference 106,022, Exhibit 1011, Jul. 10, 2015.
110 Interference 106,022, Exhibit 1012, Jul. 10, 2015.
111 Interference 106,022, Exhibit 1013, Jul. 10, 2015.
112 Interference 106,022, Exhibit 1014, Jul. 10, 2015.
113 Interference 106,022, Exhibit 1015, Jul. 10, 2015.
114 Interference 106,022, Exhibit 1016, Jul. 10, 2015.
115 Interference 106,022, Exhibit 1017, Jul. 10, 2015.
116 Interference 106,022, Exhibit 1019, Jul. 10, 2015.
117 Interference 106,022, Exhibit 1020, Jul. 10, 2015.
118 Interference 106,022, Exhibit 1021, Jul. 10, 2015.
119 Interference 106,022, Exhibit 1022, Jul. 10, 2015.
120 Interference 106,022, Exhibit 1023, Jul. 10, 2015.
121 Interference 106,022, Exhibit 1024, Jul. 10, 2015.
122 Interference 106,022, Exhibit 1025, Jul. 10, 2015.
123 Interference 106,022, Exhibit 1026, Jul. 10, 2015.
124 Interference 106,022, Exhibit 1027, Jul. 10, 2015.
125 Interference 106,022, Exhibit 1028, Jul. 10, 2015.
126 Interference 106,022, Exhibit 1029, Jul. 10, 2015.
127 Interference 106,022, Exhibit 1030, Jul. 10, 2015.
128 Interference 106,022, Exhibit 1041, Jul. 10, 2015.
129 Interference 106,022, Exhibit 1042, Jul. 10, 2015.
130 Interference 106,022, Exhibit 1043, Jul. 10, 2015.
131 Interference 106,022, Exhibit 1044, Jul. 10, 2015.
132 Interference 106,022, Exhibit 1047, Sep. 11, 2015.
133 Interference 106,022, Exhibit 1048, Sep. 11, 2015.
134 Interference 106,022, Exhibit 1049, Sep. 11, 2015.
135 Interference 106,022, Exhibit 1050, Sep. 11, 2015.
136 Interference 106,022, Exhibit 1051, Sep. 11, 2015.
137 Interference 106,022, Exhibit 1052, Sep. 11, 2015.
138 Interference 106,022, Exhibit 1053, Sep. 11, 2015.
139 Interference 106,022, Exhibit 2001, Jul. 10, 2015.
140 Interference 106,022, Exhibit 2002, Jul. 10, 2015.
141 Interference 106,022, Exhibit 2003, Jul. 10, 2015.
142 Interference 106,022, Exhibit 2004, Jul. 10, 2015.
143 Interference 106,022, Exhibit 2005, Jul. 10, 2015.
144 Interference 106,022, Exhibit 2006, Jul. 10, 2015.
145 Interference 106,022, Exhibit 2007, Jul. 10, 2015.
146 Interference 106,022, Exhibit 2008, Jul. 10, 2015.
147 Interference 106,022, Exhibit 2009, Jul. 10, 2015.
148 Interference 106,022, Exhibit 2010, Jul. 10, 2015.
149 Interference 106,022, Exhibit 2011, Jul. 10, 2015.
150 Interference 106,022, Exhibit 2012, Jul. 10, 2015.
151 Interference 106,022, Exhibit 2013, Jul. 10, 2015.
152 Interference 106,022, Exhibit 2014, Jul. 10, 2015.
153 Interference 106,022, Exhibit 2015, Jul. 10, 2015.
154 Interference 106,022, Exhibit 2016, Jul. 10, 2015.
155 Interference 106,022, Exhibit 2017, Jul. 10, 2015.
156 Interference 106,022, Exhibit 2018, Jul. 10, 2015.
157 Interference 106,022, Exhibit 2021, Jul. 10, 2015.
158 Interference 106,022, Exhibit 2022, Jul. 10, 2015.
159 Interference 106,022, Exhibit 2023, Jul. 10, 2015.
160 Interference 106,022, Exhibit 2025, Jul. 10, 2015.
161 Interference 106,022, Exhibit 2026, Jul. 10, 2015.
162 Interference 106,022, Exhibit 2027, Jul. 10, 2015.
163 Interference 106,022, Exhibit 2028, Jul. 10, 2015.
164 Interference 106,022, Exhibit 2029, Jul. 10, 2015.
165 Interference 106,022, Exhibit 2030, Jul. 10, 2015.
166 Interference 106,022, Exhibit 2041, Jul. 10, 2015.
167 Interference 106,022, Exhibit 2064, Jul. 10, 2015.
168 Interference 106,022, Exhibit 2065, Jul. 31, 2015.
169 Interference 106,022, Exhibit 2065, Sep. 11, 2015.
170 Interference 106,022, Exhibit 2066, Jul. 31, 2015.
171 Interference 106,022, Exhibit 2066, Sep. 11, 2015.
172 Interference 106,022, Exhibit 2067, Jul. 31, 2015.
173 Interference 106,022, Exhibit 2067, Sep. 11, 2015.
174 Interference 106,022, Exhibit 2068, Jul. 31, 2015.
175 Interference 106,022, Exhibit 2068, Sep. 11, 2015.
176 Interference 106,022, Exhibit 2069, Jul. 31, 2015.
177 Interference 106,022, Exhibit 2069, Sep. 11, 2015.
178 Interference 106,022, Exhibit 2070, Jul. 31, 2015.
179 Interference 106,022, Exhibit 2070, Sep. 11, 2015.
180 Interference 106,022, Exhibit 2071, Jul. 31, 2015.
181 Interference 106,022, Exhibit 2071, Sep. 11, 2015.
182 Interference 106,022, Exhibit 2072, Sep. 11, 2015.
183 Interference 106,022, Exhibit 2073, Sep. 11, 2015.
184 Interference 106,022, Exhibit 2074, Sep. 11, 2015.
185 Interference 106,022, Exhibit 2075, Sep. 11, 2015.
186 Interference 106,022, Exhibit 2077, Sep. 11, 2015.
187 Interference 106,022, Exhibit 2078, Sep. 11, 2015.
188 Interference 106,022, Exhibit 2079, Sep. 11, 2015.
189 Interference 106,022, Exhibit 2080, Sep. 11, 2015.
190 Interference 106,022, Exhibit 2081, Sep. 11, 2015.
191 Interference 106,022, Exhibit 2082, Sep. 11, 2015.
192 Interference 106,022, Exhibit 2083, Sep. 11, 2015.
193 Interference 106,022, Exhibit 2084, Sep. 11, 2015.
194 Interference 106,022, Exhibit 2085, Sep. 11, 2015.
195 Interference 106,022, Exhibit 2086, Sep. 11, 2015.
196 Interference 106,022, Exhibit 2087, Sep. 11, 2015.
197 Interference 106,022, Exhibit 2088, Sep. 11, 2015.
198 Interference 106,022, Exhibit 2089, Sep. 11, 2015.
199 Interference 106,022, Exhibit 2090, Sep. 11, 2015.
200 Interference 106,022, Exhibit 2091, Sep. 11, 2015.
201 Interference 106,022, Exhibit 2092, Sep. 11, 2015.
202 Interference 106,022, Exhibit 2093, Sep. 11, 2015.
203 Interference 106,022, Exhibit 2094, Sep. 11, 2015.
204 Interference 106,022, Paper 12 John G. Devane Notice of Related Proceedings, Apr. 22, 2015.
205 Interference 106,022, Paper 123 Recro Motion 1, Jul. 10, 2015.
206 Interference 106,022, Paper 14 Redeclaration 37 C.F.R. 203(c), Apr. 23, 2015.
207 Interference 106,022, Paper 140 Recro Motion 5, Jul. 10, 2015.
208 Interference 106,022, Paper 142 Purdue Pharma Exhibit List, Jul. 10, 2015.
209 Interference 106,022, Paper 143 Purdue Pharma Motion 1, Jul. 10, 2015.
210 Interference 106,022, Paper 144 Purdue Pharma Motion 2, Jul. 10, 2015.
211 Interference 106,022, Paper 145 Purdue Pharma Motion 4, Jul. 10, 2015.
212 Interference 106,022, Paper 148 Recro Motion 3, Jul. 10, 2015.
213 Interference 106,022, Paper 152 Order-Responsive Motion, Jul. 24, 2015.
214 Interference 106,022, Paper 154 Purdue Motion 5, Jul. 31, 2015.
215 Interference 106,022, Paper 159 Recro Updated Exhibit List, Jul. 31, 2015.
216 Interference 106,022, Paper 163 Recro Motion 6, Jul. 31, 2015.
217 Interference 106,022, Paper 18 Purdue Pharma Motion List, May 7, 2015.
218 Interference 106,022, Paper 187, Purdue Opposition 1, Sep. 11, 2015.
219 Interference 106,022, Paper 187, Recro Opposition 1, Sep. 11, 2015.
220 Interference 106,022, Paper 188, Recro Opposition 2, Sep. 11, 2015.
221 Interference 106,022, Paper 189, Recro Opposition 5, Sep. 11, 2015.
222 Interference 106,022, Paper 19 Recro Motion List, May 8, 2015.
223 Interference 106,022, Paper 190, Recro Opposition 5, Sep. 11, 2015.
224 Interference 106,022, Paper 191, Purdue Opposition 3, Sep. 11, 2015.
225 Interference 106,022, Paper 192, Purdue Opposition 5, Sep. 11, 2015.
226 Interference 106,022, Paper 193, Purdue Opposition 6, Sep. 11, 2015.
227 Interference 106,022, Paper 20 Recro Statement Concerning Other Proceedings, May 8, 2015.
228 Interference 106,022, Paper 204, Recro Substitute Opposition 5, Sep. 18, 2015.
229 Interference 106,022, Paper 205, Recro Substitute Opposition 4, Sep. 18, 2015.
230 Interference 106,022, Paper 21 Order Authorizing Motions and Setting Times, May 19, 2015.
231 Interference 106,022, Paper 22 Redeclaration 37 C.F.R. 41.203(c), May 19, 2015.
232 Interference 106,022, Paper 25 Decision Miscellaneous Motion Bd R 121(a)(3), Jul. 2, 2015.
233 Interference 106,022, Paper 27 Recro Exhibit List, Jul. 10, 2015.
234 Interference 106,022, Paper 6 Oshlack Notice of Related Proceedings, Apr. 22, 2015.
235 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/025914 dated Aug. 28, 2012.
236 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035767 dated Nov. 13, 2012.
237 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035768 dated Nov. 13, 2012.
238 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035770 dated Nov. 13, 2012.
239 International Search Report and Written Opinion for PCT/US2007/020041, dated Feb. 25, 2008.
240 Investigator agreements between the study organizers and certain of the principal investigators, 2003.
241 J. Control Release Aug. 5, 1999; 60(2-3):391-7.
242 J. Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," Pain and Symptom Manag., vol. 4 (3), pp. 146-151,1989.
243 J. Lapin et al., "Guidelines for Use of Controlled Release Oral Morphine in Cancer Pain Management," Cancer Nursing, vol. 12 (4), pp. 202-208, (1989).
244 J. Pharm. Pharmacol (Dec. 1996); 48(12):1276-84.
245 J. Pharm. Sci. (Feb. 1993); 82(2):113-26.
246 J. W. Barnhart, .et. al., Gas Chromatographic Determination of Hydrocodone in Serum, 130 J. Chromatography 243-49, Abstract (1977).
247 Johnson, Sarah J., "Opioid Safety in Patients With Renal or Hepatic Dysfunction" Pain Treatment Topics pp. 1-9 (Release date Jun. 2007; updated Nov. 30, 2007).
248 Kadian® Prescribing Information 2006.
249 Kaiko et al., "A Single-Dose Study of the Effect of Food Ingestion and Timing of Dose Administration on the Pharmacokinetic Profile of 30-mg Sustained-Release Morphine Sulfate Tablets," Current Terapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878.
250 Kaiko R.F., "Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient," Anesthesiology and Pain Management 1991 pp. 193-212.
251 Lippold, B. C., Constant or Pulsed Delivery of Active Substance?, Pharmacie in uns Zeit, Jan. 13-31, 1990, No. 1.
252 M.H. Beers: "The Merck Index, 11th edition," 1989, Merck & Co. CP002606249.
253 Maccarrone C. et al.," Single Dose Pharmacokinetics of Kapanol™ a New Oral Sustained-Release Morphine Formulation,"Clinical Drug Investigation 1994:7 (5) 262-274.
254 McTaggart, Celia M., et al., "The evaluation of formulation and processing conditions of a melt granulation process," International Journal of Pharmaceutics, vol. 19, pp. 139-148 (1984).
255 Merk Index, 13th edition, entry 4806: hydrocodone (2001).
256 MS Contin® Prescribing Information 2012.
257 MS Contin-Frequency of Daily Dosing (NDTI)-Jun. 1991-May 1992.
258 MS Contin-Frequency of Daily Dosing, Jan.-Nov. 1990.
259 Office Action issued in connection with Chinese Patent Application No. CN 201210130057.4 on Oct. 11, 2014.
260 Office Action issued in connection with Japanese patent application No. 2013-168584 on Sep. 16, 2014.
261 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Apr. 10, 2012.
262 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Apr. 30, 2013.
263 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Aug. 13, 2014.
264 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 19, 2013.
265 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 27, 2012.
266 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Feb. 26, 2014.
267 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Nov. 5, 2012.
268 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Oct. 9, 2014.
269 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Sep. 4, 2013.
270 Office Action issued in connection with U.S. Appl. No. 13/833,263 on Feb. 6, 2014.
271 Office Action issued in connection with U.S. Appl. No. 13/833,263 on Jun. 23, 2014.
272 Office Action issued in connection with U.S. Appl. No. 13/833,263 on Oct. 7, 2014.
273 Office Action issued in connection with U.S. Appl. No. 14/094,968 on Feb. 6, 2014.
274 Office Action issued in connection with U.S. Appl. No. 14/094,968 on Jun. 24, 2014.
275 Office Action issued in connection with U.S. Appl. No. 14/094,968 on Oct. 3, 2014.
276 Office Action issued in connection with U.S. Appl. No. 14/483,395 on Oct. 9, 2014.
277 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Apr. 10, 2012.
278 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Apr. 30, 2013.
279 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Aug. 13, 2014.
280 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Feb. 26, 2014.
281 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Nov. 5, 2012.
282 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Sep. 4, 2014.
283 Office Action issued on Jul. 27, 2012, in connection with European Application No. 01 992 565.0-2123.
284 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 177 508.8-2123.
285 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 179 086.3-2123.
286 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 945.7.
287 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 984.6.
288 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 181 032.3.
289 Office Action issued on May 24, 2011, in connection with European Application No. 10 179 087.1-2123.
290 Opinion Expressed by the Board of Appeal in the Summons to Oral Proceedings in Case EP02026247 ( May 24, 2011).
291 Oxycontin® Prescribing Information 2010.
292 Patient consent forms, apparently for four study participants, 2003.
293 Physicians Desk Reference 1994, 48th Edition, pp. 1821-1824.
294 Physician's Desk Reference 57th ed. 2003 p. 1184-1185 (package insert information for ACTIQ).
295 Plummer JL, et al., "A comparison of Kapanol™ (A new sustained release morphine formulation) MST Continus™ and mophine solution in cancer patients: pharmcodynamic aspects," (Abstract 1000) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
296 Portenoy et al. "Fentanyl Buccal Tablet (FBT) for Relief of Breakthrough Pain in Opioid-Treated Patients with Chronic Low Back Pain", Current Medical Research and Opinion, vol. 23(7), pp. 223-233, 2007.
297 Portenoy et al. "Fentanyl Buccal Tablet (FBT) for Relief of Breakthrough Pain in Opioid-Treated Patients with Chronic Low Back Pain: A Randomized, Placebo-Controlled Study", ASRA 06, Final Abstract, Submitted Aug. 4, 2007.
298 R.K. Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Pudue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989).
299 R.K. Portenoy, et al., "A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacolinetics and Pharmacodynamics of Kapanol® Capsules Given Every 24 hours and Every 12 hours with MS Contin® Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain," Memorial Hospital IRB Protocol pp. 379-381, 1993.
300 Ratain M J et al., "Population Pharmacodynamic Study of Amonafide: A Cancer and Leukemia Group B Study," Journal of Clinical Oncology, Grune and Stratton, New York, NY, US, vol. 13, No. 3, Mar. 1995, pp. 741-747, XP008044974 ISSN: 0732-183X.
301 Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food," The Hospice Journal, vol. 6(4) 1990, pp. 17-30.
302 S. Bloomfield, et al., "Analgesic Efficacy and Potency of Two Oral Controlled-Release Morphine Preparations Clin. Pharmacol,"Ther., vol. 53, No. 4, pp. 469-478, 1993.
303 Santus G., and Baker. R.W., "Osmotic drug delivery: a review of the patent literature," J Controlled Release (1995) vol. 35 pp. 1-21.
304 Schaefer, T., et al., "Melt granulation in a laboratory scale high shear mixer," Drug Development and Industrial Pharmacy, vol. 16, No. 8, pp. 1249-1277 (1990).
305 Setiabidu R et al., "Dapsone N-Acetylation, Metoprolol, Alpha-Hydroxylation, and S-Mephenytoin 4-Hydroxylation Polymorphisms in an Indonesian Population: A Cocktail and Extended Phenotyping Assessment Trail," Clinical Pharmacology & Therapeutics, Mosby-Year Book, St Louis, MO, US, vol. 56, No. 2, Aug. 1994, pp. 142-153, XP008044975 ISSN: 0009-9236.
306 Shah et al., J. Cont. Rel. (1989) 9:169-175.
307 Siepmann et al., "A New Model Describing the Swelling and Drug Release Kinetics from Hydroxypropyl Methylcellulose Tablets", Journ. of Pharmaceutical Sciences, vol. 88, No. 1, pp. 65-72, Jan. 1999.
308 Summons to Attend Oral Proceedings issued in connection with European Patent Application No. 05019453.9 on Jul. 23, 2010.
309 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 01992565.0.
310 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10177508.8.
311 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179086.3.
312 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179087.1.
313 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10180984.6.
314 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10181032.3.
315 Sung et al., "Effect of Formulation Variables on Drug and Polymer Release from HPMC-Based Matrix Tablets", International Journ. of Pharmaceutics vol. 142, pp. 53-60, 1996.
316 Sustained Release Medications, Noyes Data Corp., pp. 3,4, 10-15, 96-99, 335-337 (1980).
317 T. Hunt and R. Kaiko, "Comparison of the Pharmacokinetic Profiles of Two Oral Controlled-Release Morphine Formulation in Healthy Young Adults," Clin. Thera., vol. 13, No. 4, pp. 482-488, 1991.
318 The Merck Index, eleventh edition, pp. 757 and 1100 (1989).
319 Thomsen, L. Juul, "Prolonged Release Matrix Pellets prepared by Melt Pelletization II. Hydrophobic Substances as Meltable Binders," vol. 20, No. 77, pp. 1179-1197 (1994).
320 Thomsen, L. Juul, "Prolonged Release Matrix Pellets Prepared by Melt Pelletization. Part IV: Drug Particles Size, and Binder Composition," Pharmaceutical Technology Europa, pp. 19-24 (Oct. 1994).
321 Thomsen, L. Juul, "Utilizing melt pelletization technique for the preparation of prolonged release products," Pelletization, (material elaborated by assistant prof. Lars Jull Thomsen, Department of Pharmaceutics, Royal Danish School of Pharmacy of the Die course "Pelletization Technology," Nov. 1992, 106 pp. plus 3 appendices.
322 Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization I. Process Variables," Drug Development and Industrial Pharmacy, vol. 19, No. 15, pp. 1867-1887 (1993).
323 Toner G, Cramond T, Bishop, et al., "Randomized double blind, phase III crossover study of a new sustained-release oral mophine fornulation, Kapanol™ capsules," (Abstract 1001) International Association for the Study on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
324 Trandemate ER® Prescribing Information 2005.
325 Vashi et al., "Clinical Pharmacology and Pharmacokinetics of Once-Daily Hydromorphone Hydrochloride Extended-Release Capsules", J. Clin. Pharmacal, vol. 45, pp. 547-554, 2005.
326 Viriden et al., "Investigation of Critical Polymer Properties for Polymer Release and Swelling of HPMC Matrix Tablets", EP Journal of Pharmaceutical Sciences 36, pp. 297-309, 2009.
327 Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Containing Certain Active Moieties/Active Ingredients Based on a Biopharmaceutics Classification System (Issued Jan. 1999, Posted Feb. 16, 1999).
328 Webster, PTI-821: Sustained-Release Oxycodon Investig. Drugs, vol. 16, (3), pp. 1-8, 2007.
329 West R. J., et al., "Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol™ capsules," (Abstract 997) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
330 Wiktionary, "dispersed," p. 1, http://en.wiktionary.org/wiki/disperse retrived on Apr. 30, 2006.
331 Yokokawa N., et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," Postgrad Med J. (1991) 67 (Suppl. 2) pp. S50-S54.
332 Zimm et al., Pharmaceutical Development and Technology, 1(1), 37-42 (1996) "Drug Release from a Multiparticulate Pallet System."
333 Zohydro ER Hydrocodone Bitartrate Extended-Release (HC-ER) Dec. 7, 2012.
334 Zohydro ER Package Insert revised Oct. 2013.
US9572804 * 9 Feb 2016 21 Feb 2017 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572805 * 9 Feb 2016 21 Feb 2017 Purdue Pharma L.P. Controlled release hydrocodone formulations
Clasificación internacional A61P25/04, A61K9/54, A61K9/20, C07D489/02, A61K31/194, A61K31/46, A61K9/52, A61K9/26, A61K9/22, A61K9/00, A61K9/14, A61K31/485, A61K9/24
Clasificación cooperativa A61K31/485, A61K9/2077, A61K9/2018, A61K9/2031, A61K9/205, A61K9/2009, A61K9/2013, A61K9/0053, A61K9/2086, A61K9/2054, A61K9/0004, A61K31/46, A61K9/141, A61K9/2027, A61K9/2072, A61K31/194